World's Best Scientists 2026 revealed!
Award Badge
Best Female Scientists
2025

D-Index & Metrics

Best Female Scientists

D-Index
111
Citations
76097
World Ranking
824
National Ranking
501

Medicine

D-Index
116
Citations
80920
World Ranking
4258
National Ranking
2329

Research.com Recognitions

  • 2025 - Research.com Best Female Scientists Award

Overview

Alice T. Shaw is affiliated with Harvard University in the United States and is an active contributor to medical and cancer research literature. Their work primarily focuses on pulmonary and respiratory medicine, oncology, molecular biology, and cancer research, with significant contributions to the understanding and treatment of lung cancer.

Their research covers a broad range of topics, including:

  • Lung Cancer Treatments and Mutations
  • Lung Cancer Research Studies
  • Lung Cancer Diagnosis and Treatment
  • Cancer Genomics and Diagnostics
  • Cancer therapeutics and mechanisms
  • Colorectal Cancer Treatments and Studies
  • Cancer Immunotherapy and Biomarkers

Alice T. Shaw has published extensively in fields relating to medicine and biochemistry, genetics, and molecular biology. The major subfields of their study include pulmonary and respiratory medicine, oncology, molecular biology, cancer research, and pathology and forensic medicine.

Frequent publication venues for their work include:

  • Journal of Clinical Oncology
  • Journal of Thoracic Oncology
  • Cancer Research
  • Lung Cancer
  • Annals of Oncology

The scientist has collaborated regularly with several co-authors, notably:

  • Benjamin Solomon
  • Justin F. Gainor
  • Enriqueta Felip
  • Anna Polli
  • W. Marston Linehan

Among the recent papers that feature their contributions are:

  • First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer, 2020, New England Journal of Medicine
  • Three subtypes of lung cancer fibroblasts define distinct therapeutic paradigms, 2021, Cancer Cell
  • Lorlatinib Versus Crizotinib in Patients With Advanced ALK-Positive Non-Small Cell Lung Cancer: 5-Year Outcomes From the Phase III CROWN Study, 2024, Journal of Clinical Oncology
  • Efficacy and safety of first-line lorlatinib versus crizotinib in patients with advanced, ALK-positive non-small-cell lung cancer: updated analysis of data from the phase 3, randomised, open-label CROWN study, 2022, The Lancet Respiratory Medicine
  • MET Alterations Are a Recurring and Actionable Resistance Mechanism in ALK-Positive Lung Cancer, 2020, Clinical Cancer Research

Best Publications

  • Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer

    Eunice L. Kwak;Yung-Jue Bang;D. Ross Camidge;Alice T. Shaw

  • Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer

    Alice T. Shaw;Dong Wan Kim;Kazuhiko Nakagawa;Takashi Seto

  • Genotypic and Histological Evolution of Lung Cancers Acquiring Resistance to EGFR Inhibitors

    Lecia V. Sequist;Belinda A. Waltman;Dora Dias-Santagata;Subba Digumarthy

  • Tumour heterogeneity and resistance to cancer therapies

    Ibiayi Dagogo-Jack;Alice T Shaw

  • Clinical Features and Outcome of Patients With Non–Small-Cell Lung Cancer Who Harbor EML4-ALK

    Alice T. Shaw;Beow Y. Yeap;Mari Mino-Kenudson;Subba R. Digumarthy

  • Alectinib versus Crizotinib in Untreated ALK-Positive Non–Small-Cell Lung Cancer

    Solange Peters;D. Ross Camidge;Alice T. Shaw;Shirish Gadgeel

  • Crizotinib in ROS1-Rearranged Non–Small-Cell Lung Cancer

    Alice T. Shaw;Sai Hong I. Ou;Yung Jue Bang;D. Ross Camidge

  • ROS1 Rearrangements Define a Unique Molecular Class of Lung Cancers

    Kristin Bergethon;Alice T. Shaw;Sai Hong Ignatius Ou;Ryohei Katayama

  • Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer

    Alice T. Shaw;Dong Wan Kim;Ranee Mehra;Daniel S W Tan

  • STK11/LKB1 Mutations and PD-1 Inhibitor Resistance in KRAS-Mutant Lung Adenocarcinoma.

    Ferdinandos Skoulidis;Michael E. Goldberg;Danielle M. Greenawalt;Matthew D. Hellmann

  • Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study.

    D. Ross Camidge;Yung Jue Bang;Eunice L. Kwak;A. John Iafrate

  • Mechanisms of Acquired Crizotinib Resistance in ALK-Rearranged Lung Cancers

    Ryohei Katayama;Alice T. Shaw;Alice T. Shaw;Tahsin M. Khan;Tahsin M. Khan;Mari Mino-Kenudson

  • Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials

    Robert C Doebele;Alexander Drilon;Alexander Drilon;Luis Paz-Ares;Salvatore Siena

  • Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung Cancer

    Justin F. Gainor;Leila Dardaei;Satoshi Yoda;Luc Friboulet

  • Inertial Focusing for Tumor Antigen–Dependent and –Independent Sorting of Rare Circulating Tumor Cells

    Emre Ozkumur;Ajay M. Shah;Jordan C. Ciciliano;Benjamin L. Emmink

  • Effect of crizotinib on overall survival in patients with advanced non-small-cell lung cancer harbouring ALK gene rearrangement: a retrospective analysis.

    Alice T. Shaw;Beow Y. Yeap;Benjamin J. Solomon;Gregory J. Riely

  • EGFR Mutations and ALK Rearrangements Are Associated With Low Response Rates to PD-1 Pathway Blockade in Non-Small Cell Lung Cancer: A Retrospective Analysis

    Justin F. Gainor;Alice T. Shaw;Lecia V. Sequist;Xiujun Fu

  • Endogenous oncogenic K-rasG12D stimulates proliferation and widespread neoplastic and developmental defects

    David A Tuveson;Alice T Shaw;Alice T Shaw;Alice T Shaw;Nicholas A Willis;Daniel P Silver

  • The ALK Inhibitor Ceritinib Overcomes Crizotinib Resistance in Non–Small Cell Lung Cancer

    Luc Friboulet;Nanxin Li;Ryohei Katayama;Christian C. Lee

  • Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.

    Scott J. Rodig;Mari Mino-Kenudson;Sanja Dacic;Beow Y. Yeap

Frequent Co-Authors

Justin F. Gainor
Justin F. Gainor Harvard University
Sai-Hong Ignatius Ou
Sai-Hong Ignatius Ou University of California, Irvine
Jeffrey A. Engelman
Jeffrey A. Engelman Novartis Institutes for BioMedical Research (NIBR)
Lecia V. Sequist
Lecia V. Sequist Harvard University
Dong-Wan Kim
Dong-Wan Kim Seoul National University Hospital
D. Ross Camidge
D. Ross Camidge University of Colorado Anschutz Medical Campus
Benjamin Solomon
Benjamin Solomon Peter MacCallum Cancer Centre
Mari Mino-Kenudson
Mari Mino-Kenudson Harvard University
Shirish M. Gadgeel
Shirish M. Gadgeel University of Michigan–Ann Arbor
Beow Y. Yeap
Beow Y. Yeap Harvard University

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Exploring a career in medicine doesn’t always mean following the traditional path to becoming a doctor. Online healthcare degrees provide flexible and affordable options for those interested in various roles within the medical field.

For aspiring nurses seeking advanced practice and leadership positions, the cheapest DNP programs offer accessible routes to a Doctor of Nursing Practice. If you want to specialize in medications and their management, consider accredited online pharmacy programs, which can lead to a Doctor of Pharmacy (PharmD).

Not every healthcare role involves direct patient care. A online bachelor's in health information management prepares you for essential roles in managing medical records and health data systems. Meanwhile, those who prefer administrative work can enroll in online medical billing and coding courses to start a quick-entry career in the healthcare industry.

These online programs help you build a rewarding career in healthcare, whether your interest lies in clinical, administrative, or technical roles.

Best Scientists Citing Alice T. Shaw

Trending Scientists

Recently Published Articles